

## **The European Patent Office announces intention to grant of Composition-of-Matter patent for Scandion Oncology's lead compound SCO-101**

**If granted, the patent will cover the commercial solid form of SCO-101 until at least 2042.**

Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, has been informed that the European Patent Office (EPO) intends to grant the Composition-of-Matter patent for Scandion's lead compound SCO-101. This decision follows the positive opinion issued by the EPO in January 2023.

If granted, the new patent will cover solid crystal forms of SCO-101, which includes the form of the compound that Scandion expects to be commercialized. Expiring in 2042, the patent will extend the potential commercial exclusivity period for SCO-101. This could allow Scandion to expand the development of SCO-101 into new indications and drug combinations, potentially making a future treatment available to more patients.

*"The EPO's intention to grant of the new patent is welcoming news for us. Getting the patent would put us in the unique position of having close to 20 years of patent protection on a compound already in clinical development. This long potential commercial exclusivity will be a very important element for our long-term value creation",* says Francois Martelet, CEO of Scandion.

SCO-101 is currently being clinically developed as a combination treatment for metastatic colorectal cancer and pancreatic cancer.

Scandion believes that SCO-101 can revert cancer's resistance to treatments like chemotherapy thereby making the treatments work better and longer. Today, cancer drug resistance continues to constitute a huge unmet medical need.

Following grant of the patent in Europe, Scandion expects to extend the patent to a number of countries outside Europe.

**For further information please contact:**

Johnny Stilou, CFO  
Phone: +45 2960 3532  
E-mail: [jos@scandiononcology.com](mailto:jos@scandiononcology.com)

This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on July 18, 2023, at 07.00 CET.

**Scandion Oncology** (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer's resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.



**PRESS RELEASE**  
18 July 2023 07:00:00 CEST

Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are due to cancer drug resistance. Our medicines could be relevant in several different cancers. That makes both our medical and commercial potential significant.

Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.

*This information is information that Scandion Oncology is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-07-18 07:00 CEST.*

#### **Attachments**

**The European Patent Office announces intention to grant of Composition-of-Matter patent for Scandion Oncology's lead compound SCO-101**

**The European Patent Office Announces Intention To Grant Of Composition Of Matter Patent For Scandion Oncology's Lead Compound SCO 101**